natgillin/translations-raw huggingface dataset:
It is not recommended to co- administer efavirenz and Viramune (see section 4.4), because of additive toxicity and no benefit in terms of efficacy over either NNRTI alone (for results of 2NN study, see section 5.1 Viramune immediate-release formulations).
Ne preporučuje se istodobna primjena efavirenza i Viramunea (vidjeti dio 4.4) zbog dodatne toksičnosti i izostanka koristi u smislu djelotvornosti u odnosu na sam NNRTI (za rezultate 2NN ispitivanja , vidjeti dio 5.1 Viramune tableta s formulacijama trenutnog oslobađanja).
It is not recommended to co- administer efavirenz and Viramune (see section 4.4), because of additive toxicity and no benefit in terms of efficacy over either NNRTI alone (for results of 2NN study, see section 5.1).
Ne preporučuje se istodobna primjena efavirenza i Viramunea (vidjeti dio 4.4) zbog dodatne toksičnosti i izostanka koristi u smislu djelotvornosti u odnosu na sam NNRTI (za rezultate 2 NN ispitivanja, vidjeti dio 5.1).
It is not recommended to co- administer efavirenz and Viramune (see section 4.4), because of additive toxicity and no benefit in terms of efficacy over either NNRTI alone (for results of 2NN study, see section 5.1).
Ne preporučuje se istodobna primjena efavirenza i Viramunea (vidjeti dio 4.4) zbog dodatne toksičnosti i izostanka koristi u smislu djelotvornosti u odnosu na sam NNRTI (za rezultate 2NN ispitivanja, vidjeti dio 5.1).
It is not recommended to co- administer EVOTAZ with simeprevir.
Ne preporučuje se istodobna primjena lijeka EVOTAZ i simeprevira.
It is not recommended to co- administer fosamprenavir and Viramune if fosamprenavir is not co- administered with ritonavir (see section 4.4).
Ne preporučuje se istodobna primjena fosamprenavira i Viramunea, ako se fosamprenavir ne primjenjuje u kombinaciji istodobno s ritonavirom (vidjeti dio 4.4).
It is not recommended to co- administer ketoconazole and Nevirapine Teva (see section 4.4).
Ne preporučuje se istodobna primjena ketokonazola i Nevirapina Teva (vidjeti dio 4.4.).
It is not recommended to co- administer ketoconazole and Viramune (see section 4.4).
Ne preporučuje se istodobna primjena ketokonazola i Viramunea (vidjeti dio 4.4).
It is not recommended to co- administer ketoconazole and Viramune (see section 4.4).
Ne preporučuje se istodobna primjena ketokonazola i Viramunea.
It is not recommended to co- administer lopinavir/ritonavir and telaprevir.
dozu trebati progresivno smanjivati
It is not recommended to co- administer rifampicin and Viramune (see section 4.4).
Ne preporučuje se istodobna primjena rifampicina i Viramunea (vidjeti dio 4.4).
It is not recommended to co-administer
Ne preporučuje se istodobno primjenjivati
It is not recommended to co-administer boosted PREZISTA and simeprevir.
istodobno primjenjivao u kombinaciji s
It is not recommended to co-administer boosted PREZISTA and telaprevir.
Ne preporučuje se istodobna primjena pojačane PREZISTE i telaprevira
It is not recommended to co-administer Eviplera with other NNRTIs.
Ne preporučuje se istovremena primjena lijeka Eviplera s drugim nenukleozidnim inhibitorima reverzne transkriptaze.
It is not recommended to co-administer OLYSIO with products containing St John’s wort as co-administration may result in loss of therapeutic effect of OLYSIO.
Ne preporučuje se istovremeno primjenjivati OLYSIO s pripravcima koji sadrže gospinu travu jer istovremena primjena može dovesti do gubitka terapijskog učinka lijeka OYLSIO.
It is not recommended to combine INTELENCE with any of the following medicines: tipranavir/ritonavir (anti-HIV medicine)
Ne preporučuje se kombinirati INTELENCE s bilo kojim od slijedećih lijekova: tipranavir/ritonavir (lijek protiv HIV-a)
It is not recommended to combine PREZISTA co-administered with
Ne preporučuje se istodobna primjena lijeka PREZISTA istodobno s niskom
It is not recommended to drink alcohol during treatment with Leflunomide Winthrop.
Ne preporučuje se konzumacija alkohola tijekom liječenja lijekom Leflunomide Winthrop.
It is not recommended to drive or operate machines for the first 15 days after Foscan injection, because of the recommended light exposure restrictions
Ne preporučuje se rukovati strojevima tijekom prvih 15 dana nakon injekcije Foscana, zbog preporučenog ograničenja izlaganja svjetlosti.
It is not recommended to lower the plasma tyrosine concentration by reduction or discontinuation of nitisinone, since the metabolic defect may result in deterioration of the patient’s clinical condition.
Ne preporučuje se snižavanje koncentracije tirozina u plazmi smanjivanjem ili prekidom liječenja nitizinonom, jer metabolički defekti mogu uzrokovati pogoršanje kliničkog stanja bolesnika.
It is not recommended to take Aloxi in the days following chemotherapy unless you are receiving another chemotherapy cycle.
Ne preporučuje se primjenjivati Aloxi u dane nakon kemoterapije, osim ako primate sljedeći ciklus kemoterapije.
It is not recommended to take Aloxi in the days following chemotherapy unless you are receiving another chemotherapy cycle.
Ne preporučuje se uzimati Aloxi u dane nakon kemoterapije, osim ako primate sljedeći ciklus kemoterapije.
It is not recommended to take Briviact if you are pregnant or breast-feeding, as the effects of Briviact on pregnancy and the unborn baby or the new-born child are not known.
Ne preporučuje se primjenjivati Briviact tijekom trudnoće ili dojenja jer učinci lijeka Briviact na trudnoću i nerođeno dijete ili novorođenče nisu poznati.
It is not recommended to take Vimpat if you are pregnant, as the effects of Vimpat on pregnancy and the unborn baby are not known.
Ne preporučuje se uzimanje Vimpata ako ste trudni budući da nisu poznati učinci Vimpata na trudnoću i na plod.
It is not recommended to use Mozobil for stem cell mobilisation if you have leukaemia (a cancer of the blood or bone marrow).
Ne preporučuje se primjena lijeka Mozobil za mobilizaciju matičnih stanica ako bolujete od leukemije (raka krvi ili koštane srži).
It is not recommended to use NovoThirteen and recombinant coagulation factor VIIa (another blood clotting factor) together.
Ne preporučuje se istodobna primjena lijeka NovoThirteen i rekombinantnog koagulacijskog faktora VIIa (drugi faktor zgrušavanja krvi).
It is not recommended to use REYATAZ with ritonavir for pregnant patients who are receiving both tenofovir and an H2-receptor antagonist.
Ne preporučuje se primjenjivati REYATAZ s ritonavirom u trudnica koje primaju i tenofovir i antagonist H2-receptora
It is not recommended to use REYATAZ with ritonavir for pregnant patients who are receiving both tenofovir disoproxil fumarate and an H2-receptor antagonist.
Ne preporučuje se primjenjivati REYATAZ s ritonavirom u trudnica koje primaju i tenofovirdizoprokislfumarat i antagonist H2-receptora.
It is not yet fully established whether immunocompetent individuals who have responded to hepatitis A vaccination will require booster doses as protection in the absence of detectable antibodies may be ensured by immunological memory.
Još nije u potpunosti utvrđeno treba li imunokompetentnim osobama koje su odgovorile na cijepljenje cjepivom protiv hepatitisa A docjepljivanje, budući da se zaštita u slučaju odsustva detektibilnih protutijela može osigurati imunološkim pamćenjem.
It is not yet fully established whether immunocompetent individuals who have responded to hepatitis A vaccination will require booster doses as protection in the absence of detectable antibodies may be ensured by immunological memory.
Još nije u potpunosti utvrđeno treba li imunokompetentnim osobama koje su odgovorile na cijepljenje protiv hepatitisa A docjepljivanje, budući da se, u slučaju da nema protutijela koja se mogu detektirati, zaštita može osigurati imunološkim pamćenjem.
It is not yet fully established whether immunocompetent individuals who have responded to hepatitis A vaccination will require booster doses as protection in the absence of detectable antibodies may be ensured by immunological memory.
Još nije u potpunosti utvrđeno trebaju li imunokompetentne osobe koje su odgovorile na cijepljenje protiv hepatitisa A - docjepljivanje, budući da se, u slučaju da nema mjerljivih protutijela, zaštita može osigurati imunološkom memorijom.
It is not yet fully established whether immunocompetent individuals who have responded to hepatitis A vaccination will require booster doses as protection in the absence of detectable antibodies may be insured by immunological memory.
Još nije u potpunosti utvrđeno treba li imunokompetentnim osobama koje su odgovorile na cijepljenje protiv hepatitisa A docjepljivanje, budući da se, u slučaju da nema protutijela koja se mogu detektirati, zaštita može osigurati imunološkim pamćenjem.
It is not yet known how the risk of a blood clot with IOA compares to the risk with a combined hormonal contraceptive that contains levonorgestrel.
Još nije poznato koliki je rizik od krvnog ugruška uz IOA u odnosu na rizik uz kombinirani hormonski kontraceptiv koji sadrži levonogestrel.
It is not yet known how the risk of a blood clot with Zoely compares to the risk with a combined hormonal contraceptive that contains levonorgestrel.
Još nije poznato koliki je rizik od krvnog ugruška uz Zoely u odnosu na rizik uz kombinirani hormonski kontraceptiv koji sadrži levonogestrel.
It is not yet known how the risk of VTE with CHCs that contain nomegestrol acetate in combination with estradiol compares with the risk with low dose levonorgestrel-containing CHCs.
Još nije poznato koliki je rizik od VTE uz KHK-e koji sadrže nomegestrolacetat u kombinaciji s estradiolom u usporedbi s rizikom uz KHK-e koji sadrže nisku dozu levonorgestrela.
It is not yet known how the risk of VTE with CHCs that contain nomegestrol acetate in combination with estradiol compares with the risk with low dose levonorgestrel-containing CHCs.
Još nije poznato koliki je rizik od VTE uz KOK-e koji sadrže nomegestrolacetat u kombinaciji s estradiolom u usporedbi s rizikom uz KOK-e koji sadrže nisku dozu levonorgestrela.
It is not yet known if this medicine affects fertility in women.
Još nije poznato utječe li ovaj lijek na plodnost u žena.
It is not yet known, however, whether Praluent will reduce cardiovascular disease, as data on long-term cardiovascular outcomes are still pending.
No, nije poznato hoće li Praluent smanjiti kardiovaskularnu bolest budući da se još uvijek prikupljaju podaci o dugoročnim kardiovaskularnim rezultatima.
It is not yet known, however, whether Repatha will reduce cardiovascular disease.
No, još uvijek nije poznato hoće li lijek Repatha smanjiti kardiovaskularnu bolest.
It is noted that hypersensitivity is a listed ADR in the timolol Product Information.
Napominje se da je preosjetljivost navedena u popisu nuspojava lijeka u informacijama o lijeku za timolol.
It is noted that other Angiotensin Receptor Blockers has thrombocytopenia listed as Adverse Drug Reaction (ADR) in the Product Information, as well as irbesartan in the FDA product information.
Primijećeno je da drugi blokatori receptora za angiotenzin imaju trombocitopeniju navedenu kao nuspojavu u informacijama o lijeku, kao i irbesartan u informacijama o lijeku odobrenim od strane FDA-a.
It is of note that 42 (31.6%) patients in the chemotherapy arm subsequently received an anti-PD1 treatment.
Važno je napomenuti da su 42 (31,6%) bolesnika u skupini liječenoj kemoterapijom kasnije primala anti-PD1 liječenje.
It is of primary importance to initiate Kuvan treatment as early as possible to avoid the appearance of non-reversible clinical manifestations of neurological disorders in paediatric patients and cognitive deficits and psychiatric disorders in adults due to sustained elevations of blood phenylalanine.
Od primarne je važnosti započeti liječenje Kuvanom što ranije kako bi se izbjegla pojava nereverzibilnih kliničkih manifestacija neuroloških poremećaja kod pedijatrijskih bolesnika te kognitivni nedostaci i psihijatrijski poremećaji kod odraslih, uzrokovani trajnim povećanjem koncentracije fenilalanina u krvi.
It is of relevance to highlight that 19 of the 41 cases were prescribed overdose, with a median of 5 mg.
Važno je napomenuti da je u 19 od 41 slučaja propisana prevelika doza s medijanom od 5 mg.
It is okay if there are air bubbles.
U redu je ako vidite mjehuriće zraka.
It is only for patients whose melanoma tumour cells have been shown to have a specific mutation (change) in the BRAF gene called ‘BRAF V600’.
Predviđen je samo za bolesnike čije su stanice melanoma testirane i pokazale su specifičnu mutaciju (promjenu) u svojem genu naziva „BRAF V600”.
It is only given on the first day of the chemotherapy and is followed by treatment involving a corticosteroid and a 5- HT3 antagonist.
Daje se samo prvoga dana kemoterapije, a nakon njega slijedi liječenje koje uključuje kortikosteroid i antagonist 5- HT3.
It is only indicated in the process of switching from Lixiana 30 mg (patients with one or more clinical factors for increased exposure; see table 1) to VKA, together with an appropriate VKA dose (see table 2, section 4.2).
Ova je doza indicirana samo u postupku zamjene Lixiane 30 mg AVK-om (bolesnici s jednim ili više kliničkih čimbenika za povećanu izloženost, vidjeti tablicu 1), zajedno s odgovarajućom dozom AVK- a (vidjeti tablicu 2, dio 4.2).
It is only used if the NSCLC is ‘ALK-positive’, which means that the cancer cells have certain defects affecting the gene responsible for a protein called ALK (anaplastic lymphoma kinase).
Koristi se samo ako je NSCLC pozitivan na ALK, što znači da stanice raka imaju određene nedostatke koji utječu na gen odgovoran za protein naziva kinaza anaplastičnog limfoma (engl. anaplastic lymphoma kinase, ALK).
It is only used in patients where the virus has not developed resistance to a class of HIV medicines called non- nucleoside reverse transcriptase inhibitors, tenofovir or emtricitabine, and who have HIV levels in the blood (viral load) of no more than 100,000 HIV-1 RNA copies/ml.
Koristi se samo u bolesnika kod kojih virus nije razvio rezistenciju na klasu lijekova za HIV koji se nazivaju inhibitori nenukleozidne reverzne transkriptaze, tenofovir ili emtricitabin, i kod kojih razina HIV-a u krvi (virusno opterećenje) nije veće od 100 000 HIV-1 RNK kopija/ml.
It is only used in patients who have been previously treated with other cancer medicines.
Daje se samo bolesnicima koji su prethodno liječeni drugim lijekovima protiv raka.
It is only used when the nail to fix the bone does not need ‘reaming’ (drilling to make room for nail placement).
Koristi se samo u slučajevima kada nije potrebno ponovno "ciljanje" čavla za fiksiranje kosti (bušenje kako bi se napravilo mjesta za postavljanje čavla).
It is packaged in bottles of 250 ml or 500 ml.
Pakirana je u bocama od 250 ml ili 500 ml.
It is particularly important that the medicine is not used in children under the age of 2 years (see section ‘Do not use SIMBRINZA’ above).
Posebno je važno da se ovaj lijek ne primjenjuje u djece ispod 2 godine starosti (Pogledajte dio „Ne primjenjujte SIMBRINZU“ iznad).
It is particularly important that you mention any of the following medicines:
Osobito je važno da spomenete ako uzimate bilo koji od sljedećih lijekova:
It is particularly important that you mention the following:
Osobito je važno da spomenete sljedeće:
It is particularly important to read the symptoms of a blood clot - see section 2 “Blood clots”.
Osobito je važno pročitati o simptomima krvnog ugruška – pogledajte dio 2 “Krvni ugrušci”.
It is particularly important to read the symptoms of a blood clot – see section 2 “Blood clots”).
Osobito je važno pročitati o simptomima krvnog ugruška – pogledajte dio 2 "Krvni ugrušci").
It is particularly important to tell your doctor if you are being treated with clopidogrel (an anti-platelet agent), warfarin (an anti-coagulant), or “non steroidal anti inflammatory drugs” for pain and fever (such as ibuprofen, naproxen, etoricoxib).
Posebno je važno da obavijestite liječnika ako se liječite klopidogrelom (antitrombocitni lijek), varfarinom (antikoagulans) ili nesteroidnim protuupalnim lijekovima protiv bolova i vrućice (poput ibuprofena, naproksena, etorikoksiba).
It is particularly important to tell your doctor if you are using medicines that prevent blood from clotting (oral anticoagulants, e.g. warfarin).
Osobito je važno da obavijestite svog liječnika ako primjenjujete lijekove koji sprječavaju zgrušavanje krvi (oralni antikoagulansi, npr. varfarin).
It is particularly important to try to ensure that maximal plasma levels are achieved in patients infected with Aspergillus (see sections 4.2 and 5.2 on recommended dose regimens).
Osobito je važno pokušati osigurati postizanje maksimalnih razina u plazmi bolesnika zaraženih gljivicom Aspergillus (vidjeti dijelove 4.2 i 5.2 o preporučenim režimima doziranja).
It is particularly important to understand the information in section 3 before taking this medicine.
Prije nego počnete uzimati ovaj lijek, posebno je važno da razumijete upute u dijelu 3.
It is particularly important to understand the information in section 3.
Prije nego počnete uzimati ovaj lijek, posebno je važno da razumijete upute u dijelu 3.
It is past the expiry date.
Istekao je rok valjanosti.
It is possible for it to take a few days before the full extent of tissue damage is visible.
Može proći nekoliko dana prije nego postane vidljiv potpuni opseg oštećenja kože.
It is possible that Avastin can cause hypersensitivity and/or infusion reactions (reactions related to your injection of the medicine).
Avastin može prouzročiti reakcije preosjetljivosti i/ili infuzijske reakcije (reakcije povezane s injiciranjem lijeka).
It is possible that Avastin can increase the risk of bleeding in your lungs, including coughing or spitting blood.
Avastin može povećati rizik od krvarenja u plućima, uključujući iskašljavanje krvi ili krvavi ispljuvak.
It is possible that Avastin may cause bleeding in and around your brain.
Može se dogoditi da Avastin uzrokuje krvarenje u mozgu i oko mozga.
It is possible that Avastin may increase the risk of developing holes in the gut wall.
Avastin može povećati rizik od napuknuća u stijenci crijeva.
It is possible that no transfusions will be needed.
Moguće je da Vam transfuzije više neće biti potrebne.
It is possible that the risk of side effects affecting the muscles may be higher when any of these medicines (and some others that can affect muscles) is taken during treatment with Cubicin.
Moguće je da rizik od nastanka nuspojava koje pogađaju mišiće bude viši ako se bilo koji od tih lijekova (i neki drugi koji mogu utjecati na mišiće) uzima tijekom liječenja Cubicinom.
It is postulated that these actions protect endothelial cells.
Pretpostavlja se da te aktivnosti štite endotelne stanice.
It is preferable not to take this medicine during pregnancy .
Ne preporučuje se uzimanje lijeka Clopidogrel dura za vrijeme trudnoće.
It is preferable not to take this medicine during pregnancy.
Ne preporučuje se uzimanje Clopidogrela Krka d.d. za vrijeme trudnoće.
It is preferable not to take this medicine during pregnancy.
Ne preporučuje se uzimanje lijeka Klopidogrel Teva Pharma za vrijeme trudnoće.
It is preferable not to take this medicine during pregnancy.
Ne preporučuje se uzimanje ovog lijeka za vrijeme trudnoće.
It is preferable not to take this product during pregnancy.
Ne preporučuje se uzimanje lijeka Klopidogrel Acino za vrijeme trudnoće.
It is preferable not to use this product during pregnancy and breast-feeding.
Ne preporučuje se uzimanje lijeka Klopidogrel Teva Generics B.V za vrijeme trudnoće.
It is preferable that Emtricitabine/Tenofovir disoproxil Zentiva is taken with food.
Poželjno je uzimati Emtricitabine/Tenofovir disoproxil Zentiva s hranom.
It is preferable to avoid the use of Cosentyx in pregnancy.
Preporučuje se izbjegavati primjenu Cosentyxa u trudnoći.
It is preferable to avoid the use of Stelara in pregnancy.
Preporučuje se izbjegavati primjenu Stelare u trudnoći.
It is prepared from the highly purified virus-like particles (VLPs) of the major capsid L1 protein from the same four HPV types (6, 11, 16, 18) in qHPV vaccine Gardasil or Silgard and from 5 additional HPV types (31, 33, 45, 52, 58).
Pripremljeno je od visokopročišćenih čestica nalik virusu glavnog L1 proteina kapside četiri tipa HPV-a (6, 11, 16 i 18) kakva sadrže cjepiva qHPV Gardasil ili Silgard i 5 dodatnih tipova HPV-a (31, 33, 45, 52 i 58).
It is presented as a clear and colourless solution in a colourless type I glass 2 mL or 10 mL vial with a V-shaped and flat bottom, respectively, with a bromobutyl stopper, closed with an aluminium seal.
U obliku je bistre i bezbojne otopine koja se nalazi u bezbojnoj bočici od stakla tipa I od 2 ml ili 10 ml s ravnim dnom u obliku slova V i bromobutilnim čepom zatvorenim aluminijskim zatvaračem.
It is printed on the labels and on the carton.
Otisnut je na naljepnicama i na kutiji.
It is produced by a method known as ‘recombinant DNA technology’: it is made by a bacterium into which a gene (DNA) has been introduced, which makes it able to produce anakinra.
Proizvodi se metodom poznatom kao „tehnologija rekombinantne DNK”: stvara ga bakterija u koju je unesen gen (DNK) koji omogućuje proizvodnju anakinre.
It is produced by a method known as ‘recombinant DNA technology’: the enzyme is made by cells into which a gene (DNA) has been introduced that makes them able to produce laronidase.
Proizvodi se metodom poznatom kao „tehnologija rekombinantne DNK”: enzim tvore stanice u koje je unesen gen (DNK) koji im omogućuje proizvodnju laronidaze.
It is produced by a method known as ‘recombinant DNA technology’: the hormone is made by yeast cells into which a gene (DNA) has been introduced that makes them able to produce it.
Proizvodi se metodom pod nazivom „tehnologija rekombinantne DNA": hormon proizvode stanice kvasca u koje je unesen gen (DNA) koji im omogućuje proizvodnju.
It is produced by recombinant DNA technology in baby hamster kidney cells (BHK) into which the human factor VIII gene has been introduced.
Proizvodi se tehnologijom rekombinantne DNK u stanicama bubrega mladog hrčka (engl. baby hamster kidney, BHK) u koju je uveden gen za ljudski faktor VIII.
It is produced by recombinant DNA technology in Chinese hamster ovary (CHO) cells.
Proizveden je tehnologijom rekombinantne DNK u stanicama jajnika kineskog hrčka (CHO – Chinese hamster ovary).
It is produced by switching on the gene for α-galactosidase A in cells.
Stvara se aktivacijom gena za alfa-galaktozidazu A u stanicama.
It is provided in a 100 ml brown glass bottle with a white, child resistant screw cap.
Isporučuje se u smeđoj staklenoj boci od 100 ml s bijelim navojnim zatvaračem sigurnim za djecu.
It is provided in a ready-to-use syringe, containing a single dose (0.5 ml) for injection, Not all pack sizes may be marketed.
Isporučena je u štrcaljki spremnoj za uporabu koja sadrži jednostruku dozu (0,5 ml) za injekciju, Na tržištu se ne moraju nalaziti sve veličine pakovanja.
It is provided in a vial containing ten doses (0.5 ml each) for injection, Not all pack sizes may be marketed.
Isporučena je u bočici koja sadrži deset doza (0,5 ml svaka) za injekciju, Na tržištu se ne moraju nalaziti sve veličine pakovanja.
It is provided in clear glass vials with a rubber stopper and sealed with an aluminium cap.
Dostupna je u bočicama od prozirnoga stakla s gumenim čepom, dodatno učvršćenim aluminijskim zatvaračem.
It is provided in: a ready-to-use syringe, containing a single dose of 0.5 ml for injection;
Dostupna je u: štrcaljki spremnoj za uporabu koja sadrži jednokratnu dozu od 0,5 ml za injekciju;
It is provided with a 1 ml pre-filled glass syringe of solvent for reconstitution (water for injections) and one needle.
Priložena je i staklena napunjena štrcaljka s 1 ml otapala (voda za injekcije) za rekonstituciju, i jedna igla.
It is prudent to reserve third generation cephalosporins for the treatment of clinical conditions, which have responded poorly, or are expected to respond poorly, to other classes of antimicrobials or first generation cephalosporins.
Preporuča se korištenje treće generacije cefalosporina za terapiju kliničkih stanja koja su slabo reagirala, ili se pretpostavlja da će slabo reagirati na ostale klase antimikrobnih sredstava ili cefalosporine prve generacije.